Evaluation of the NHS R67 Monogenic Hearing Loss Panel in a Single UK Centre
Clinical Otolaryngology · 2026-09 · 51 (5) · 708-713
DOI: 10.1111/coa.70125 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Otolaryngology, online erschienen am 27.05.2026. Verfasst von Irmak Sakin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Otolaryngology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. Hauptthemen laut MEDLINE: Hearing Loss, Genetic Testing. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
The NHS R67 genetic hearing loss panel was introduced in England in 2021 and has expanded the diagnostic approach to hearing loss. This study aimed to evaluate the diagnostic yield and clinical utility of the panel in paediatric and adult patients assessed through a tertiary multidisciplinary genetic hearing loss clinic.
Methods
A retrospective case review was conducted of patients referred to a tertiary genetic hearing loss multidisciplinary clinic who underwent R67 monogenic hearing loss analysis. Demographic data, referral patterns, family history, hearing loss severity, age at diagnosis, congenital cytomegalovirus testing, radiological findings, genetic results and hearing habilitation or rehabilitation strategies were analysed descriptively. Diagnostic yield was compared across hearing loss severity categories.
Results
Eighty‐four patients were included, comprising 46 children and 38 adults. A monogenic diagnosis was identified in 48.8% of patients overall, with a higher yield in children than adults: 63.0% versus 31.6%, respectively. Variants of uncertain significance were identified in 7.1% of patients. Hearing loss severity was significantly associated with identification of a genetic cause, although 35% of patients with an identified genetic cause had mild or moderate hearing loss.
Conclusion
The R67 monogenic hearing loss panel is a valuable diagnostic tool for investigating sensorineural hearing loss in children and adults, particularly when delivered through multidisciplinary clinics that support counselling and clinical decision‐making. Further reporting is needed to refine referral criteria and support patient selection for targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Otolaryngology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
- Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
ORCID-Profile: Irmak Sakin, Chloe Swords, Jessica Ball, Elizabeth Oakley-Hannibal, Harriet Cunniffe, Simon Holden, Manohar Bance, Jessica Bewick
Zitieren
APA
Sakin, I., Swords, C., Ball, J., Oakley-Hannibal, E., Cunniffe, H., Holden, S., Bance, M., & Bewick, J. (2026). Evaluation of the NHS R67 Monogenic Hearing Loss Panel in a Single UK Centre. Clinical Otolaryngology, 51(5), 708-713. https://doi.org/10.1111/coa.70125
Vancouver
Sakin I, Swords C, Ball J, Oakley-Hannibal E, Cunniffe H, Holden S, et al. Evaluation of the NHS R67 Monogenic Hearing Loss Panel in a Single UK Centre. Clinical Otolaryngology. 2026;51(5):708-713. doi:10.1111/coa.70125
BibTeX
@article{Sakin2026,
author = {Sakin, Irmak and Swords, Chloe and Ball, Jessica and Oakley-Hannibal, Elizabeth and Cunniffe, Harriet and Holden, Simon and Bance, Manohar and Bewick, Jessica},
title = {Evaluation of the NHS R67 Monogenic Hearing Loss Panel in a Single UK Centre},
journal = {Clinical Otolaryngology},
year = {2026},
volume = {51},
number = {5},
pages = {708--713},
doi = {10.1111/coa.70125}
}
EUVIMED